Practical use of a multicenter clinical research support system connected to electronic medical records

Author(s):  
Shirou Manabe ◽  
Toshihiro Takeda ◽  
Atsushi Hattori ◽  
Masashi Yamamoto ◽  
Yoshie Shimai ◽  
...  
2019 ◽  
Vol 17 (4) ◽  
Author(s):  
Veronica Neves Fialho Queiroz ◽  
Andrea da Costa Moreira de Oliveira ◽  
Renato Carneiro de Freitas Chaves ◽  
Lucas Araújo de Borges Moura ◽  
Daniel Sousa César ◽  
...  

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
William Tillett ◽  
Michelle Skornicki ◽  
Patricia Prince ◽  
Robert Suruki ◽  
Edward Lee ◽  
...  

Abstract Background Psoriasis (PSO) is an inflammatory skin condition, impacting physical and psychological well-being. PSO patients may develop psoriatic arthritis (PsA), a painful joint disease that further impacts quality of life. The objective was to examine rates of metabolic disease and depression in patients with PSO and PsA. Methods Claims data linked to electronic medical records were examined (Jan-2007-Mar-2018). Prevalent PSO patients were followed until end of data collection and categorized based on development of PsA (PSO+PsA cohort; defined by ICD9/10 codes in patients without PsA at baseline). Follow-up rates of comorbidities, including metabolic disease and depression, were compared for those with/without PsA, presented as cases per 1,000 patient-years (1000PY). Results Progression to PsA occurred in 2,311 (12%) patients. Follow-up rates of hyperlipidemia, hypertension, diabetes, and cardiovascular disease in the PSO+PsA cohort were 1.4-times (326 vs 234/1000PY), 1.6-times (357 vs 228/1000PY), 1.7-times (119 vs 72/1000PY), and 1.4-times (71 vs 50/1000PY) that observed in the PSO-only cohort, respectively. In patients without baseline metabolic disease, higher rates in PSO+PsA vs PSO-only remained (approximately 1.5-times and 1.3-times higher rates of hypertension and hyperlipidemia, respectively). The rate of depression was 140 vs 92/1000PY in the PSO+PsA vs PSO-only cohort; when examined in patients without baseline depression, rates were about half that observed in the overall population (72 vs 49/1000PY). Conclusion PSO+PsA patients had a substantial clinical burden, characterized by 40-70% higher rates of metabolic disease and depression than for patients who did not progress to PsA. Disclosures W. Tillett: Consultancies; AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB Pharma. Grants/research support; AbbVie, Celgene and Lilly. M. Skornicki: Other; Employee of Aetion. P. Prince: Other; Employee of Aetion. R. Suruki: Other; Employee of UCB Pharma. E. Lee: Other; Employee of UCB Pharma. A. Louder: Other; Employee of Aetion.


BMJ Open ◽  
2017 ◽  
Vol 7 (7) ◽  
pp. e013956 ◽  
Author(s):  
Helen C Walkey ◽  
Akaal Kaur ◽  
Vassiliki Bravis ◽  
Ian F Godsland ◽  
Shivani Misra ◽  
...  

2018 ◽  
Vol 4 (1) ◽  
pp. 014001 ◽  
Author(s):  
Wen-Wai Yim ◽  
Amanda J Wheeler ◽  
Catherine Curtin ◽  
Todd H Wagner ◽  
Tina Hernandez-Boussard

Sign in / Sign up

Export Citation Format

Share Document